-- New $3.8 million DOD contract extension will fund non-clinical safety studies to support a three-month seasonal prophylaxis Phase 2b…
Pleasanton, CA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a…
Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of Alltrna, Appointed…
Commercial cannabis cultivator partners with other growers, Grow Light Design and The Cannabis Research Coalition to examine the impact of…
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed…
Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the…
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of…
Bioventure Bioventure logo Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureAlvotech (NASDAQ:…
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureREYKJAVIK, Iceland and DUBAI,…
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4BERKELEY,…